Assessment of the paradoxical effect of caspofungin in therapy of candidiasis

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 4, 2006, Pages 1293-1297

  Clemons, Karl V ^a,b,c   Espiritu, Marife ^a   Parmar, Rachana ^a   Stevens, David A ^a,b,c  

^a CALIFORNIA INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; COLONY FORMING UNIT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FUNGUS GROWTH; FUNGUS ISOLATION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REPRODUCIBILITY;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDIASIS; DOSE-RESPONSE RELATIONSHIP, DRUG; KIDNEY; MALE; MICE; PEPTIDES, CYCLIC; REPRODUCIBILITY OF RESULTS;

EID: 33645797825     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.4.1293-1297.2006     Document Type: Article

References (25)

1. Abruzzo, G. K., A. M. Flattery, C. J. Gill, L. Kong, J. G. Smith, V. B. Pikounis, J. M. Balkovec, A. F. Bouffard, J. F. Dropinski, H. Rosen, H. Kropp, and K. Bartizal. 1997. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother. 41:2333-2338.
2. Abruzzo, G. K., C. J. Gill, A. M. Flattery, L. Kong, C. Leighton, J. G. Smith, V. B. Pikounis, K. Bartizal, and H. Rosen. 2000. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob. Agents Chemother. 44:2310-2318.
3. Clemons, K. V., and D. A. Stevens. 2001. Efficacy of the partricin derivative SPA-S-753 against systemic murine candidosis. J. Antimicrob. Chemother. 47:183-186.
4. Deresinski, S. C., and D. A. Stevens. 2003. Caspofungin. Clin. Infect. Dis. 36:1445-1457.
5. Graybill, J. R., R. Bocanegra, M. Luther, A. Fothergill, and M. J. Rinaldi. 1997. Treatment of murine Candida krusei or Candida glabrata infection with L-743,872. Antimicrob. Agents Chemother. 41:1937-1939.
6. Graybill, J. R., L. K. Najvar, M. F. Luther, and A. W. Fothergill. 1997. Treatment of murine disseminated candidiasis with L-743,872. Antimicrob. Agents Chemother. 41:1775-1777.
7. Gresser-Burns, M. E., C. J. Shanholtzer, L. R. Peterson, and D. N. Gerding. 1987. Occurrence and reproducibility of the "skip" phenomenon in bactericidal testing of Staphylococcus aureus. Diagn. Microbiol. Infect. Dis. 6:335-342.
8. Hanson, L. H., A. M. Perlman, K. V. demons, and D. A. Stevens. 1991. Synergy between cilofungin and amphotericin B in a murine model of candidiasis. Antimicrob. Agents Chemother. 35:1334-1337.
9. Hernandez, S., J. L. López-Ribot, L. K. Najvar, D. I. McCarthy, R. Bocanegra, and J. R. Graybill. 2004. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive candida esophagitis. Antimicrob. Agents Chemother. 48:1382-1383.
10. Imai, J. K., G. Singh, K. V. Clemons, and D. A. Stevens. 2004. Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob. Agents Chemother. 48:4063-4066.
11. Kirkpatrick, W. R., S. Perea, B. J. Coco, and T. F. Patterson. 2002. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob. Agents Chemother. 46:2564-2568.
12. Kondo, N., K. Kuwahara-Arai, H. Kuroda-Murakami, E. Tateda-Suzuki, and K. Hiramatsu. 2001. Eagle-type methicillin resistance: new phenotype of high methicillin resistance under mec regulator gene control. Antimicrob. Agents Chemother. 45:815-824.
13. Lachin, J. M. 1999. Worst-rank score analysis with informatively missing observations in clinical trials. Control. Clin. Trials 20:408-422.
14. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
15. O'Sullivan, C. E., M. Kasai, A. Francesconi, V. Petraitis, R. Petraitiene, A. M. Kelaher, A. A. Sarafandi, and T. J. Walsh. 2003. Development and validation of a quantitative real-time PCR assay using fluorescence resonance energy transfer technology for detection of Aspergillus fumigatus in experimental invasive pulmonary aspergillosis. J. Clin. Microbiol. 41:5675-5682.
16. Petraitiene, R., V. Petraitis, A. H. Groll, T. Sein, R. L. Schaufele, A. Francesconi, J. Bacher, N. A. Avila, and T. J. Walsh. 2002. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob. Agents Chemother. 46:12-23.
17. Pfaller, M. A., S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, and D. J. Diekema. 2004. Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates. J. Clin. Microbiol. 42:3117-3119.
18. Shah, P. M. 1982. Paradoxical effect of antibiotics. I. The 'Eagle effect.' J. Antimicrob. Chemother. 10:259-260.
19. Shih, W. 2002. Problems in dealing with missing data and informative censoring in clinical trials. Curr. Control Trials Cardiovasc. Med. 3:4.
20. Stevens, D. A., M. Espiritu, and R. Parmar. 2004. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob. Agents Chemother. 48:3407-3411.
21. Stevens, D. A., T. C. White, D. S. Perlin, and C. P. Selitrennikoff. 2005. Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn. Microbiol. Infect. Dis. 51:173-178.
22. Stevens, D. L., A. E. Gibbons, R. Bergstrom, and V. Winn. 1988. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J. Infect. Dis. 158:23-28.
23. Stille, W., and H. Uffelmann. 1973. Paradoxic bactericidal effect of penicillins on enterococci (Eagle effect). Dtsch. Med. Wochenschr. 98:611-613. (In German.)
24. Stratton, C. W., C. Liu, H. B. Ratner, and L. S. Weeks. 1987. Bactericidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studies. Antimicrob. Agents Chemother. 31:1014-1016.
25. Yourassowsky, E., M. P. Van der Linden, M. J. Lismont, F. Crockaert, and Y. Glupczynski. 1988. Bactericidal effect and regrowth of Streptococcus faecalis exposed to amoxicillin following beta-lactamase. Chemotherapy 34:462-466.